Interesting comparison to RAP.
MEB has already completed trials at a prestigious USA hospital, submitted for FDA regulatory approval, signed commercial arrangements, and has a commercially driven CEO based in the heart of Med Tech opportunities - USA. It too also has blue sky potential but it trades at a significant discount to RAP. Perhaps the higher cash burn is still playing a role in this.
The sell side looks very thin and if Jack can deliver on his promised opportunities he mentioned in the 1/4ly update it should rerate imo.
MEB Price at posting:
20.5¢ Sentiment: Buy Disclosure: Held
